SCHEMBL1358451

SCHEMBL1358451

[CH]=CC(C)CCC=CCC

nearest known ligand 0.31

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.30
MAPT P10636 2/20 0.30
FFAR1 O14842 1/20 0.30
CYP19A1 P11511 1/20 0.30
RXRA P19793 1/20 0.30
PPARG P37231 1/20 0.30
OXER1 Q8TDS5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7499539 0.76 TRPA1 (0.35) ALDH1A1MAPTFFAR1CYP19A1RXRA
SCHEMBL835461 0.76 ALDH1A1 (0.30) ALDH1A1MAPTFFAR1CYP19A1RXRA
SCHEMBL7499542 0.76 TRPA1 (0.35) ALDH1A1MAPTFFAR1CYP19A1RXRA
SCHEMBL6702321 0.76
SCHEMBL27483485 0.74 ALDH1A1 (0.30) ALDH1A1
SCHEMBL107762 0.74
SCHEMBL107763 0.74
SCHEMBL30139864 0.72 ALDH1A1 (0.33) ALDH1A1MAPTFFAR1CYP19A1RXRA
SCHEMBL21411540 0.71
SCHEMBL387577 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11931445-B2 Composition comprising baicalin L'OREAL (FR) 2024-03-19 US disclosed
WO-2023067251-A1 COMPOSITION FOR USE IN THE CUTANEOUS SYNTHESIS OF HYALURONIC ACID, IN AN IMMUNO-CUTANEOUS RESPONSE AND TO IMPROVE SKIN JR (FR) 2023-04-27 WO disclosed
EP-3558253-B1 COMPOSITION COMPRISING BAICALIN OREAL (FR) 2022-12-28 EP disclosed
US-20200093724-A1 COMPOSITION COMPRISING BAICALIN L'OREAL (FR) 2020-03-26 US disclosed
EP-3558253-A1 COMPOSITION COMPRISING BAICALIN L'Oreal (FR) 2019-10-30 EP disclosed
WO-2018115360-A1 COMPOSITION COMPRISING BAICALIN, A FATTY ACID ESTER AND AN ALKYLPOLYGLYCOSIDE L'OREAL (FR) 2018-06-28 WO disclosed
WO-2018115493-A1 COMPOSITION COMPRISING BAICALIN L'OREAL (FR) 2018-06-28 WO disclosed
US-20110288100-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN PURDUE PHARMA L.P. (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11931445-B2 Composition comprising baicalin KRT18, S100A6, DSG1 ALDH1A1 2732/4885MAPT 1721/4885FFAR1 3093/4885
US-20110288100-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN OPRL1, OPRK1, MTNR1A ALDH1A1 652/4885MAPT 2712/4885FFAR1 1385/4885
US-20200093724-A1 COMPOSITION COMPRISING BAICALIN KRT18, S100A6, DSG1 ALDH1A1 2732/4885MAPT 1721/4885FFAR1 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.